<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kavanagh ME</submitter><funding>Commonwealth (University of Cambridge) Scholarship</funding><funding>Cambridge Commonwealth Trust</funding><funding>Cambridge Overseas Trust</funding><funding>Wellcome Trust</funding><funding>Biotechnology and Biological Sciences Research Council</funding><funding>Engineering and Physical Sciences Research Council</funding><pagination>1924-35</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5026067</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(17)</volume><pubmed_abstract>The cyclo-dipeptide substrates of the essential M. tuberculosis (Mtb) enzyme CYP121 were deconstructed into their component fragments and screened against the enzyme. A number of hits were identified, one of which exhibited an unexpected inhibitor-like binding mode. The inhibitory pharmacophore was elucidated, and fragment binding affinity was rapidly improved by synthetic elaboration guided by the structures of CYP121 substrates. The resulting inhibitors have low micromolar affinity, good predicted physicochemical properties and selectivity for CYP121 over other Mtb P450s. Spectroscopic characterisation of the inhibitors' binding mode provides insight into the effect of weak nitrogen-donor ligands on the P450 heme, an improved understanding of factors governing CYP121-ligand recognition a</pubmed_abstract><journal>ChemMedChem</journal><pubmed_title>Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors.</pubmed_title><pmcid>PMC5026067</pmcid><funding_grant_id>BB/I019227/1</funding_grant_id><funding_grant_id>EP/K039520/1</funding_grant_id><funding_grant_id>GR080083/Z/06</funding_grant_id><funding_grant_id>BB/I019669/1</funding_grant_id><pubmed_authors>Gilbert SH</pubmed_authors><pubmed_authors>Munro AW</pubmed_authors><pubmed_authors>Kavanagh ME</pubmed_authors><pubmed_authors>McLean KJ</pubmed_authors><pubmed_authors>Abell C</pubmed_authors><pubmed_authors>Coyne AG</pubmed_authors><pubmed_authors>Davis HJ</pubmed_authors><pubmed_authors>Gray JL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors.</name><description>The cyclo-dipeptide substrates of the essential M. tuberculosis (Mtb) enzyme CYP121 were deconstructed into their component fragments and screened against the enzyme. A number of hits were identified, one of which exhibited an unexpected inhibitor-like binding mode. The inhibitory pharmacophore was elucidated, and fragment binding affinity was rapidly improved by synthetic elaboration guided by the structures of CYP121 substrates. The resulting inhibitors have low micromolar affinity, good predicted physicochemical properties and selectivity for CYP121 over other Mtb P450s. Spectroscopic characterisation of the inhibitors' binding mode provides insight into the effect of weak nitrogen-donor ligands on the P450 heme, an improved understanding of factors governing CYP121-ligand recognition a</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Sep</publication><modification>2026-05-03T19:31:43.833Z</modification><creation>2026-04-07T19:33:32.085Z</creation></dates><accession>S-EPMC5026067</accession><cross_references><pubmed>27432475</pubmed><doi>10.1002/cmdc.201600248</doi></cross_references></HashMap>